Ravindra Uppaluri, MD, PhD, is the chair of otolaryngology at Brigham and Women's Hospital, director of head and neck surgical oncology at Dana-Farber Brigham Cancer Center, and an associate professor of otolaryngology/head and neck surgery at Harvard Medical School.
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world care for patients with resectable head and neck cancer.
Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck cancer treatment.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
